×
Entrez Id:
1029
Gene Symbol:
CDKN2A
CDKN2A
Malignant neoplasm of liver
0.590
PosttranslationalModification
BEFREE
RESULTS The incidence of FHIT and p16 methylation in serum from the liver cancer group was 51.8% and 67.9%, respectively.
30773529
2019
×
Entrez Id:
1029
Gene Symbol:
CDKN2A
CDKN2A
Malignant neoplasm of liver
0.590
AlteredExpression
BEFREE
The p16 protein expressions in liver cancer and para-carcinoma tissues were detected via immunohistochemistry (IHC), and the correlations of p16 positive expression with ultrasound parameters were also analyzed.
30509095
2019
×
Entrez Id:
1029
Gene Symbol:
CDKN2A
CDKN2A
Malignant neoplasm of liver
0.590
Biomarker
BEFREE
These results are significant because they suggest that nucleolar p14ARF can be used as early prognostic marker in chronic liver disease to reliably identify patients with high risk for developing liver cancer .
29228217
2018
×
Entrez Id:
1029
Gene Symbol:
CDKN2A
CDKN2A
Malignant neoplasm of liver
0.590
Biomarker
CTD_human
Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer.
27064257
2016
×
Entrez Id:
1029
Gene Symbol:
CDKN2A
CDKN2A
Malignant neoplasm of liver
0.590
Biomarker
BEFREE
Yet Bmi1 functions independent of Ink4A /Arf repression in liver cancer development.
19934271
2009
×
Entrez Id:
1029
Gene Symbol:
CDKN2A
CDKN2A
Malignant neoplasm of liver
0.590
AlteredExpression
BEFREE
Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A ) activity in rat liver carcinogenesis and human liver cancer .
16317707
2005
×
Entrez Id:
1029
Gene Symbol:
CDKN2A
CDKN2A
Malignant neoplasm of liver
0.590
Biomarker
CTD_human
Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A ) activity in rat liver carcinogenesis and human liver cancer .
16317707
2005
×
Entrez Id:
1029
Gene Symbol:
CDKN2A
CDKN2A
Malignant neoplasm of liver
0.590
Biomarker
RGD
Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A ) activity in rat liver carcinogenesis and human liver cancer .
16317707
2005
×
Entrez Id:
1029
Gene Symbol:
CDKN2A
CDKN2A
Malignant neoplasm of liver
0.590
Biomarker
CTD_human
Abnormalities of the ARF-p53 pathway in primary angiosarcomas of the liver.
12378512
2002
×
Entrez Id:
1029
Gene Symbol:
CDKN2A
CDKN2A
Malignant neoplasm of liver
0.590
Biomarker
RGD
De novo methylation of the p16INK4A gene in early preneoplastic liver and tumors induced by folate/methyl deficiency in rats.
12359353
2002
×
Entrez Id:
1029
Gene Symbol:
CDKN2A
CDKN2A
Malignant neoplasm of liver
0.590
Biomarker
RGD
Sequential changes in hepatocarcinogenesis induced by diethylnitrosamine plus thioacetamide in Fischer 344 rats: induction of gankyrin expression in liver fibrosis, pRB degradation in cirrhosis, and methylation of p16(INK4A) exon 1 in hepatocellular carcinoma.
11301474
2001
×
Entrez Id:
1029
Gene Symbol:
CDKN2A
CDKN2A
Malignant neoplasm of liver
0.590
GeneticVariation
BEFREE
The purpose of the current investigation was to define the prevalence of genetic alterations in p16 and beta-catenin in NNK-induced rat liver cancer to determine if the molecular mechanisms seen in human tumors are the same in this animal model.
11238187
2001
×
Entrez Id:
1029
Gene Symbol:
CDKN2A
CDKN2A
Malignant neoplasm of liver
0.590
PosttranslationalModification
BEFREE
Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients.
9892188
1999
×
Entrez Id:
1029
Gene Symbol:
CDKN2A
CDKN2A
Malignant neoplasm of liver
0.590
Biomarker
BEFREE
Alterations of CDKN2 (MTS1/p16INK4A ) gene in paraffin-embedded tumor tissues of human stomach, lung, cervix and liver cancers .
9873831
1998
×
Entrez Id:
1029
Gene Symbol:
CDKN2A
CDKN2A
Malignant neoplasm of liver
0.590
PosttranslationalModification
BEFREE
Infrequent alterations of the p16INK4A gene in liver cancer .
8760583
1996